Nisa Investment Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Nisa Investment Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$812	Hold	584	–	–	﹤0.01%	2786
2025 Q4	$1.41K	Hold	584	–	–	﹤0.01%	2663
2025 Q3	$1.06K	Hold	584	–	–	﹤0.01%	2735
2025 Q2	$695	Sell	584 -375	-39%	-$515	﹤0.01%	2811
2025 Q1	$1.95K	Buy	959 +859	+859%	+$4.63K	﹤0.01%	2478
2024 Q4	$602	Buy	+100	New	+$727	﹤0.01%	2791
2023 Q4	–	Sell	-12	Closed	-$115	–	2641
2023 Q3	$115	Buy	+12	New	+$139	﹤0.01%	2727

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nisa Investment Advisors's ACRV Position: Q1 2026 in Review

Nisa Investment Advisors held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 584 shares worth $812. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Nisa Investment Advisors first reported a position in ACRV in Q3 2023 and has held it in 7 quarters since. The position peaked at $1.95K in Q1 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Nisa Investment Advisors held 584 shares of Acrivon Therapeutics worth $812 as of Q1 2026.
Nisa Investment Advisors left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2786 holding.
Nisa Investment Advisors first reported a position in Acrivon Therapeutics in Q3 2023 and has held it in 7 quarters since.
Nisa Investment Advisors's Acrivon Therapeutics position peaked at $1.95K in Q1 2025.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.